The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
The company might finally become an oncology player.
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.